11 research outputs found

    ОказаниС экстрСнной мСдицинской ΠΏΠΎΠΌΠΎΡ‰ΠΈ Π½Π° Π΄ΠΎΠ³ΠΎΡΠΏΠΈΡ‚Π°Π»ΡŒΠ½ΠΎΠΌ этапС ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Π°ΠΌ с острым ΠΈΠ½Ρ„Π°Ρ€ΠΊΡ‚ΠΎΠΌ ΠΌΠΈΠΎΠΊΠ°Ρ€Π΄Π° ΠΈ острым ΠΈΡˆΠ΅ΠΌΠΈΡ‡Π΅ΡΠΊΠΈΠΌ ΠΈΠ½ΡΡƒΠ»ΡŒΡ‚ΠΎΠΌ Π² Π³ΠΎΡ€ΠΎΠ΄Π΅ МосквС: Ρ€ΠΎΠ»ΡŒ авиамСдицинских Π±Ρ€ΠΈΠ³Π°Π΄ Ρ†Π΅Π½Ρ‚Ρ€Π° экстрСнной мСдицинской ΠΏΠΎΠΌΠΎΡ‰ΠΈ (Π’Π΅Ρ€Ρ€ΠΈΡ‚ΠΎΡ€ΠΈΠ°Π»ΡŒΠ½Ρ‹ΠΉ Ρ†Π΅Π½Ρ‚Ρ€ ΠΌΠ΅Π΄ΠΈΡ†ΠΈΠ½Ρ‹ катастроф)

    Get PDF
    The increase in the number of patients with complications of cardiovascular diseases and the need for early diagnosis of such complications and the early initiation of treatment already at the prehospital stage leads to an increasingΒ  need for more frequent use of helicopter medical equipment, as well as for equipping aviation medical teams with highly qualified specialists. TheΒ  formation of a network of vascular invasive centers in the Moscow region,Β  modern equipment and its use in air ambulance conditions require constant improvement of skills among medical workers. All this undoubtedly leads to positive results, the mortality rate from heart attacks and strokes decreases, the duration of treatment and the period of rehabilitation of patients areΒ  reduced. It should be noted that even 10 years ago, medical helicopters were used in the elimination of medical consequences in road accidents, fires and emergencies. Today, aviation medical teams are involved in more than 50% of cases with cardiovascular diseases, which undoubtedly speaks of theΒ  prospects for the development of medical aviation in large cities. Рост числа ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с сСрдСчно-сосудистыми заболСваниями, Π½Π΅ΠΎΠ±Ρ…ΠΎΠ΄ΠΈΠΌΠΎΡΡ‚ΡŒ быстрой транспортировки  ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² Π² стационар с ΠΏΡ€ΠΎΠ²Π΅Π΄Π΅Π½ΠΈΠ΅ΠΌ Ρ€Π°Π½Π½Π΅ΠΉ диагностики  ΠΈ своСврСмСнного лСчСния Π½Π° Π΄ΠΎΠ³ΠΎΡΠΏΠΈΡ‚Π°Π»ΡŒΠ½ΠΎΠΌ этапС ΠΎΠ±ΡƒΡΠ»Π°Π²Π»ΠΈΠ²Π°ΡŽΡ‚ Π²ΠΎΠ·Ρ€Π°ΡΡ‚Π°ΡŽΡ‰ΡƒΡŽ ΠΏΠΎΡ‚Ρ€Π΅Π±Π½ΠΎΡΡ‚ΡŒ Π² Π±ΠΎΠ»Π΅Π΅ Ρ‡Π°ΡΡ‚ΠΎΠΌΒ ΠΈΡΠΏΠΎΠ»ΡŒΠ·ΠΎΠ²Π°Π½ΠΈΠΈ Π²Π΅Ρ€Ρ‚ΠΎΠ»Π΅Ρ‚Π½ΠΎΠΉ мСдицинской Ρ‚Π΅Ρ…Π½ΠΈΠΊΠΈ ΠΈΒ  Π½Π°Π»ΠΈΡ‡ΠΈΠ΅ спСциалистов высокой ΠΊΠ²Π°Π»ΠΈΡ„ΠΈΠΊΠ°Ρ†ΠΈΠΈ Π² составС  авиамСдицинских Π±Ρ€ΠΈΠ³Π°Π΄. Π€ΠΎΡ€ΠΌΠΈΡ€ΠΎΠ²Π°Π½ΠΈΠ΅ сСти сосудистых  ΠΈΠ½Π²Π°Π·ΠΈΠ²Π½Ρ‹Ρ… Ρ†Π΅Π½Ρ‚Ρ€ΠΎΠ² Π² московском Ρ€Π΅Π³ΠΈΠΎΠ½Π΅, соврСмСнноС ΠΎΠ±ΠΎΡ€ΡƒΠ΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΈ использованиС Π΅Π³ΠΎ Π² условиях санитарной Π°Π²ΠΈΠ°Ρ†ΠΈΠΈ Ρ‚Ρ€Π΅Π±ΡƒΡŽΡ‚ постоянного ΠΏΠΎΠ²Ρ‹ΡˆΠ΅Π½ΠΈΡ Π½Π°Π²Ρ‹ΠΊΠΎΠ² срСди  мСдицинских Ρ€Π°Π±ΠΎΡ‚Π½ΠΈΠΊΠΎΠ². ВсС это ΠΏΡ€ΠΈΠ²ΠΎΠ΄ΠΈΡ‚ ΠΊΒ  ΠΏΠΎΠ»ΠΎΠΆΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹ΠΌ Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Π°ΠΌ, Ρ‚Π°ΠΊ ΠΊΠ°ΠΊ сниТаСтся ΡΠΌΠ΅Ρ€Ρ‚Π½ΠΎΡΡ‚ΡŒΒ  ΠΎΡ‚ ΠΈΠ½Ρ„Π°Ρ€ΠΊΡ‚ΠΎΠ² ΠΈ ΠΈΠ½ΡΡƒΠ»ΡŒΡ‚ΠΎΠ², ΡΠΎΠΊΡ€Π°Ρ‰Π°ΡŽΡ‚ΡΡ сроки лСчСния ΠΈ Ρ€Π΅Π°Π±ΠΈΠ»ΠΈΡ‚Π°Ρ†ΠΈΠΈ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ². Π‘Π»Π΅Π΄ΡƒΠ΅Ρ‚ ΠΎΡ‚ΠΌΠ΅Ρ‚ΠΈΡ‚ΡŒ, Ρ‡Ρ‚ΠΎ Π΅Ρ‰Π΅ 10 Π»Π΅Ρ‚ Π½Π°Π·Π°Π΄ мСдицинскиС Π²Π΅Ρ€Ρ‚ΠΎΠ»Π΅Ρ‚Ρ‹ использовались ΠΏΡ€ΠΈ Π΄ΠΎΡ€ΠΎΠΆΠ½ΠΎ-транспортных ΠΏΡ€ΠΎΠΈΡΡˆΠ΅ΡΡ‚Π²ΠΈΡΡ…, ΠΏΠΎΠΆΠ°Ρ€Π°Ρ… ΠΈΒ Ρ‡Ρ€Π΅Π·Π²Ρ‹Ρ‡Π°ΠΉΠ½Ρ‹Ρ… ситуациях. БСгодня авиамСдицинскиС  Π±Ρ€ΠΈΠ³Π°Π΄Ρ‹ Π±ΠΎΠ»Π΅Π΅ Ρ‡Π΅ΠΌ Π² 50% случаСв задСйствованы ΠΏΡ€ΠΈΒ  эвакуации Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… с сСрдСчно-сосудистыми заболСваниями,Β  Ρ‡Ρ‚ΠΎ бСзусловно Π³ΠΎΠ²ΠΎΡ€ΠΈΡ‚ ΠΎ пСрспСктивС  развития санитарной Π°Π²ΠΈΠ°Ρ†ΠΈΠΈ Π² ΠΊΡ€ΡƒΠΏΠ½Ρ‹Ρ… Π³ΠΎΡ€ΠΎΠ΄Π°Ρ….

    Π₯роничСская обструктивная болСзнь Π»Π΅Π³ΠΊΠΈΡ… ΠΈ COVID-19: Π°ΠΊΡ‚ΡƒΠ°Π»ΡŒΠ½Ρ‹Π΅ вопросы

    Get PDF
    The problem of comorbidity of new coronaviral infection (COVID-19) and chronic obstructive pulmonary disease (COPD) is acute, considering similarity of clinical manifestations, diagnostic difficulties, the potential severe disease course. Patients with COPD represent a vulnerable group of infected SARS-CoV-2, with a complicated disease course and frequent adverse outcome. Features of the spread of the virus limit treatment and diagnosis for patients with COPD, making it difficult to provide medical care during the pandemic. The negative results of some clinical studies of antiviral drugs for patients with COVID-19 indicate the need for a search for new drugs; for this reason, analysis of the anti-inflammatory effect on the lungs in infection COVID-19 of drugs of basic COPD therapy is promising.ΠΠΊΡ‚ΡƒΠ°Π»ΡŒΠ½ΠΎΡΡ‚ΡŒ ΠΏΡ€ΠΎΠ±Π»Π΅ΠΌΡ‹ коморбидности Π½ΠΎΠ²ΠΎΠΉ коронавирусной ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠΈ COVID-19 ΠΈ хроничСской обструктивной Π±ΠΎΠ»Π΅Π·Π½ΠΈ Π»Π΅Π³ΠΊΠΈΡ… (Π₯ΠžΠ‘Π›) обусловлСна ΡΡ…ΠΎΠΆΠ΅ΡΡ‚ΡŒΡŽ клиничСских проявлСний, ΡΠ»ΠΎΠΆΠ½ΠΎΡΡ‚ΡŒΡŽ диагностики, ΠΏΠΎΡ‚Π΅Π½Ρ†ΠΈΠ°Π»ΡŒΠ½ΠΎΠΉ Ρ‚ΡΠΆΠ΅ΡΡ‚ΡŒΡŽ тСчСния ΠΈ взаимоотягощСниСм этих ΠΏΠ°Ρ‚ΠΎΠ»ΠΎΠ³ΠΈΠΉ. Π‘ΠΎΠ»ΡŒΠ½Ρ‹Π΅ Π₯ΠžΠ‘Π›, ΠΈΠ½Ρ„ΠΈΡ†ΠΈΡ€ΠΎΠ²Π°Π½Π½Ρ‹Π΅ SARS-CoV-2, ΠΏΡ€Π΅Π΄ΡΡ‚Π°Π²Π»ΡΡŽΡ‚ собой ΡƒΡΠ·Π²ΠΈΠΌΡƒΡŽ Π³Ρ€ΡƒΠΏΠΏΡƒ Π»ΠΈΡ† с ослоТнСнным Ρ‚Π΅Ρ‡Π΅Π½ΠΈΠ΅ΠΌ ΠΈ часто нСблагоприятным исходом Π±ΠΎΠ»Π΅Π·Π½ΠΈ. ΠžΡΠΎΠ±Π΅Π½Π½ΠΎΡΡ‚ΠΈ распространСния вируса Π½Π°ΠΊΠ»Π°Π΄Ρ‹Π²Π°ΡŽΡ‚ Π·Π½Π°Ρ‡ΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹Π΅ ограничСния Π½Π° многочислСнныС диагностичСскиС ΠΈ Π»Π΅Ρ‡Π΅Π±Π½Ρ‹Π΅ мСроприятия ΠΏΡ€ΠΈ Π₯ΠžΠ‘Π›, затрудняя ΠΎΠΊΠ°Π·Π°Π½ΠΈΠ΅ мСдицинской ΠΏΠΎΠΌΠΎΡ‰ΠΈ Π±ΠΎΠ»ΡŒΠ½Ρ‹ΠΌ Π΄Π°Π½Π½ΠΎΠΉ ΠΊΠ°Ρ‚Π΅Π³ΠΎΡ€ΠΈΠΈ Π² ΠΏΠ΅Ρ€ΠΈΠΎΠ΄ ΠΏΠ°Π½Π΄Π΅ΠΌΠΈΠΈ Π½Π° всСх Π΅Π΅ этапах. ΠΠ΅ΠΎΠ±Ρ…ΠΎΠ΄ΠΈΠΌΠΎΡΡ‚ΡŒ поиска Π½ΠΎΠ²Ρ‹Ρ… тСрапСвтичСских Ρ€Π΅ΡˆΠ΅Π½ΠΈΠΉ ΠΏΡ€ΠΎΠ΄ΠΈΠΊΡ‚ΠΎΠ²Π°Π½Π° ΠΎΡ‚Ρ€ΠΈΡ†Π°Ρ‚Π΅Π»ΡŒΠ½Ρ‹ΠΌΠΈ Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Π°ΠΌΠΈ Ρ‚Π΅ΠΊΡƒΡ‰ΠΈΡ… клиничСских исслСдований ΠΏΠΎ ΠΈΠ·ΡƒΡ‡Π΅Π½ΠΈΡŽ эффСктивности примСнСния ряда ΠΏΡ€Π΅ΠΏΠ°Ρ€Π°Ρ‚ΠΎΠ² Ρƒ Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… COVID-19; пСрспСктивным прСдставляСтся ΠΈΠ·ΡƒΡ‡Π΅Π½ΠΈΠ΅ дСйствия Π½Π° SARS-CoV-2 ΠΏΡ€Π΅ΠΏΠ°Ρ€Π°Ρ‚ΠΎΠ² Π±Π°Π·ΠΎΠ²ΠΎΠΉ Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ Π₯ΠžΠ‘Π› с Π΄ΠΎΠΊΠ°Π·Π°Π½Π½Ρ‹ΠΌ ΠΏΡ€ΠΎΡ‚ΠΈΠ²ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹ΠΌ дСйствиСм Π½Π° Π±Ρ€ΠΎΠ½Ρ…ΠΎΠ»Π΅Π³ΠΎΡ‡Π½ΡƒΡŽ систСму

    ΠœΠΎΠ½ΠΎΡ†ΠΈΡ‚Ρ‹ ΠΊΡ€ΠΎΠ²ΠΈ Π² ΠΏΠΎΠ΄Π΄Π΅Ρ€ΠΆΠ°Π½ΠΈΠΈ баланса дСструктивных ΠΈ Ρ€Π΅ΠΏΠ°Ρ€Π°Ρ‚ΠΈΠ²Π½Ρ‹Ρ… процСссов Π² сосудистом эндотСлии ΠΏΡ€ΠΈ ΠΈΡˆΠ΅ΠΌΠΈΡ‡Π΅ΡΠΊΠΎΠΉ ΠΊΠ°Ρ€Π΄ΠΈΠΎΠΌΠΈΠΎΠΏΠ°Ρ‚ΠΈΠΈ

    Get PDF
    Highlights. The features of subsets of monocytes in combination with the levels of desquamated endotheliocytes, endothelial damage and regeneration mediators and progenitor cell migration-enhancing factors in patients with coronary heart disease and with/without ischemic cardiomyopathy were analyzed. For the first time it was shown that in patients with ischemic cardiomyopathy, compared with CHD patients without cardiomyopathy, higher desquamation of the endothelium is associated with a deficiency of non-classical monocytes and reduced migration of progenitor endothelial cells (VEGFR2+-monocytes) with regenerative potential across the bone marrow due to a deficiency of the HIF-1Ξ± mediator in the blood.Background. The development of ischemic cardiomyopathy (ICM) is an understudied process, and one of its elements may be insufficient regeneration of blood vessels due to an imbalance of subsets of monocytes in the blood.Aim. To assess subsets of monocytes and desquamated endothelial cells in combination with endothelial damage and regeneration mediators in the blood of patients with coronary heart disease (CHD) and with/without ICM.Methods. The study included 30 patients with ICM, 22 patients with coronary heart disease without cardiomyopathy aged 55–69 years, and 18 healthy donors. In whole blood, the populations of CD45–CD146+ desquamated endothelial cells and progenitor endothelial cells related to CD14+VEGFR2+Β  monocytes, intermediate CD14++CD16+Β Β  andΒ  non-classicalΒ  CD14+CD16++Β Β  monocytesΒ  wereΒ  assessedΒ  by flow cytometryΒ  usingΒ  theΒ  appropriateΒ  monoclonalΒ  antibodiesΒ  (BDΒ  Biosciens, USA). In blood plasma, the levels of hypoxia-inducible factor HIF-1Ξ±, monocyte chemoattractant protein MCP-1 and matrix metalloproteinase MMP-9 were assessed by enzyme immunoassay. The results of the analysis were considered significant at p<0.05.Results. The number of progenitor and desquamated endothelial cells was increased in both groups of patients with coronary artery disease. At the same time, in patients with ICM, the number of progenitor endothelial cells did not reach the number noted in patients with CHD without cardiomyopathy, while the number of desquamated endothelial cells reached the number noted in CHD patients without cardiomyopathy. There was a deficiency of non-classical monocytes and HIF-1Ξ± in the blood of patients with ICM, and an excess of intermediate monocytes and MCP-1 was observed in CHD patients without cardiomyopathy. The concentration of MMP-9 in patients with CHD corresponded to the norm, regardless of the presence of ICM.Conclusion. In ICM, in contrast to CHD without cardiomyopathy, vascular damage is associated with a deficiency of nonclassical monocytes and reduced endothelial repair due to insufficient migration of progenitor endothelial cells across the bone marrow due to HIF-1Ξ± deficiency in the blood.ΠžΡΠ½ΠΎΠ²Π½Ρ‹Π΅ полоТСния. Π˜Π·ΡƒΡ‡Π΅Π½Ρ‹ особСнности субпопуляционного состава ΠΌΠΎΠ½ΠΎΡ†ΠΈΡ‚ΠΎΠ² ΠΊΡ€ΠΎΠ²ΠΈ Π² комплСксС с содСрТаниСм дСсквамированных эндотСлиоцитов, ΠΌΠ΅Π΄ΠΈΠ°Ρ‚ΠΎΡ€ΠΎΠ² дСструкции эндотСлия ΠΈ Ρ„Π°ΠΊΡ‚ΠΎΡ€ΠΎΠ² ΠΌΠΈΠ³Ρ€Π°Ρ†ΠΈΠΈ Π΅Π³ΠΎ ΠΊΠ»Π΅Ρ‚ΠΎΠΊ-ΠΏΡ€Π΅Π΄ΡˆΠ΅ΡΡ‚Π²Π΅Π½Π½ΠΈΡ† Π² ΠΊΡ€ΠΎΠ²ΠΈ ΠΏΡ€ΠΈ ΠΈΡˆΠ΅ΠΌΠΈΡ‡Π΅ΡΠΊΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΠΈ сСрдца, ослоТнСнной ΠΈ Π½Π΅ ослоТнСнной ΠΈΡˆΠ΅ΠΌΠΈΡ‡Π΅ΡΠΊΠΎΠΉ ΠΊΠ°Ρ€Π΄ΠΈΠΎΠΌΠΈΠΎΠΏΠ°Ρ‚ΠΈΠ΅ΠΉ. Π’ΠΏΠ΅Ρ€Π²Ρ‹Π΅ ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΎ, Ρ‡Ρ‚ΠΎ ΠΏΡ€ΠΈ ΠΈΡˆΠ΅ΠΌΠΈΡ‡Π΅ΡΠΊΠΎΠΉ ΠΊΠ°Ρ€Π΄ΠΈΠΎΠΌΠΈΠΎΠΏΠ°Ρ‚ΠΈΠΈ, Π² ΠΎΡ‚Π»ΠΈΡ‡ΠΈΠ΅ ΠΎΡ‚ ΠΈΡˆΠ΅ΠΌΠΈΡ‡Π΅ΡΠΊΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΠΈ сСрдца Π±Π΅Π· ΠΊΠ°Ρ€Π΄ΠΈΠΎΠΌΠΈΠΎΠΏΠ°Ρ‚ΠΈΠΈ, высокая дСсквамация эндотСлия ассоциирована с Π΄Π΅Ρ„ΠΈΡ†ΠΈΡ‚ΠΎΠΌ нСклассичСских ΠΌΠΎΠ½ΠΎΡ†ΠΈΡ‚ΠΎΠ² ΠΈ ΠΏΠΎΠ½ΠΈΠΆΠ΅Π½Π½ΠΎΠΉ ΠΌΠΈΠ³Ρ€Π°Ρ†ΠΈΠ΅ΠΉ ΠΈΠ· костного ΠΌΠΎΠ·Π³Π° ΠΏΡ€ΠΎΠ³Π΅Π½ΠΈΡ‚ΠΎΡ€Π½Ρ‹Ρ… ΡΠ½Π΄ΠΎΡ‚Π΅Π»ΠΈΠ°Π»ΡŒΠ½Ρ‹Ρ… ΠΊΠ»Π΅Ρ‚ΠΎΠΊ (VEGFR2+-ΠΌΠΎΠ½ΠΎΡ†ΠΈΡ‚ΠΎΠ²) с Ρ€Π΅ΠΏΠ°Ρ€Π°Ρ‚ΠΈΠ²Π½Ρ‹ΠΌ ΠΏΠΎΡ‚Π΅Π½Ρ†ΠΈΠ°Π»ΠΎΠΌ Π²Π²ΠΈΠ΄Ρƒ Π΄Π΅Ρ„ΠΈΡ†ΠΈΡ‚Π° ΠΌΠ΅Π΄ΠΈΠ°Ρ‚ΠΎΡ€Π° HIF-1Ξ± Π² ΠΊΡ€ΠΎΠ²ΠΈ.ΠΠΊΡ‚ΡƒΠ°Π»ΡŒΠ½ΠΎΡΡ‚ΡŒ. Π˜ΡˆΠ΅ΠΌΠΈΡ‡Π΅ΡΠΊΠ°Ρ кардиомиопатия (ИКМП) развиваСтся ΠΏΠΎ ΠΌΠ°Π»ΠΎΠΈΠ·ΡƒΡ‡Π΅Π½Π½Ρ‹ΠΌ закономСрностям, Π² числС ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Ρ… ΠΌΠΎΠΆΠ΅Ρ‚ Π±Ρ‹Ρ‚ΡŒ нСдостаточная рСпарация сосудов вслСдствиС дисбаланса субпопуляций ΠΌΠΎΠ½ΠΎΡ†ΠΈΡ‚ΠΎΠ² Π² ΠΊΡ€ΠΎΠ²ΠΈ.ЦСль. ΠžΠΏΡ€Π΅Π΄Π΅Π»ΠΈΡ‚ΡŒ Ρ‡ΠΈΡΠ»Π΅Π½Π½ΠΎΡΡ‚ΡŒ субпопуляций ΠΌΠΎΠ½ΠΎΡ†ΠΈΡ‚ΠΎΠ² ΠΈ дСсквамированных ΡΠ½Π΄ΠΎΡ‚Π΅Π»ΠΈΠ°Π»ΡŒΠ½Ρ‹Ρ… ΠΊΠ»Π΅Ρ‚ΠΎΠΊ Π² комплСксС с ΠΌΠ΅Π΄ΠΈΠ°Ρ‚ΠΎΡ€Π°ΠΌΠΈ дСструкции ΠΈ Ρ€Π΅ΠΏΠ°Ρ€Π°Ρ†ΠΈΠΈ эндотСлия Π² ΠΊΡ€ΠΎΠ²ΠΈ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с ΠΈΡˆΠ΅ΠΌΠΈΡ‡Π΅ΡΠΊΠΎΠΉ болСзнью сСрдца (Π˜Π‘Π‘), ΡΡ‚Ρ€Π°Π΄Π°ΡŽΡ‰ΠΈΡ… ΠΈ Π½Π΅ ΡΡ‚Ρ€Π°Π΄Π°ΡŽΡ‰ΠΈΡ… ИКМП.ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»Ρ‹ ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹. Π’ исслСдованиС вошли 30 Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… ИКМП ΠΈ 22 ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Π° с Π˜Π‘Π‘ Π±Π΅Π· ΠΊΠ°Ρ€Π΄ΠΈΠΎΠΌΠΈΠΎΠΏΠ°Ρ‚ΠΈΠΈ Π² возрастС 55–69 Π»Π΅Ρ‚, Π° Ρ‚Π°ΠΊΠΆΠ΅ 18 Π·Π΄ΠΎΡ€ΠΎΠ²Ρ‹Ρ… Π΄ΠΎΠ½ΠΎΡ€ΠΎΠ². Π’ Ρ†Π΅Π»ΡŒΠ½ΠΎΠΉ ΠΊΡ€ΠΎΠ²ΠΈ опрСдСляли содСрТаниС CD45–CD146+Β  дСсквамированных ΡΠ½Π΄ΠΎΡ‚Π΅Π»ΠΈΠ°Π»ΡŒΠ½Ρ‹Ρ… ΠΊΠ»Π΅Ρ‚ΠΎΠΊ ΠΈ ΠΏΡ€ΠΎΠ³Π΅Π½ΠΈΡ‚ΠΎΡ€Π½Ρ‹Ρ… ΡΠ½Π΄ΠΎΡ‚Π΅Π»ΠΈΠ°Π»ΡŒΠ½Ρ‹Ρ… ΠΊΠ»Π΅Ρ‚ΠΎΠΊ, относящихся ΠΊ CD14+VEGFR2+-ΠΌΠΎΠ½ΠΎΡ†ΠΈΡ‚Π°ΠΌ, ΠΏΡ€ΠΎΠΌΠ΅ΠΆΡƒΡ‚ΠΎΡ‡Π½Ρ‹Ρ… CD14++CD16+ ΠΈ нСклассичСских ΠΌΠΎΠ½ΠΎΡ†ΠΈΡ‚ΠΎΠ² CD14+CD16++ ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΎΠΌ ΠΏΡ€ΠΎΡ‚ΠΎΡ‡Π½ΠΎΠΉ Ρ†ΠΈΡ‚ΠΎΡ„Π»ΡƒΠΎΡ€ΠΈΠΌΠ΅Ρ‚Ρ€ΠΈΠΈ с использованиСм ΡΠΎΠΎΡ‚Π²Π΅Ρ‚ΡΡ‚Π²ΡƒΡŽΡ‰ΠΈΡ… ΠΌΠΎΠ½ΠΎΠΊΠ»ΠΎΠ½Π°Π»ΡŒΠ½Ρ‹Ρ… Π°Π½Ρ‚ΠΈΡ‚Π΅Π» (BD Biosciences, БША). Π’ ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡ€ΠΎΠ²ΠΈ ΠΎΡ†Π΅Π½ΠΈΠ²Π°Π»ΠΈ ΠΊΠΎΠ½Ρ†Π΅Π½Ρ‚Ρ€Π°Ρ†ΠΈΡŽ ΠΈΠ½Π΄ΡƒΡ†ΠΈΡ€ΡƒΠ΅ΠΌΠΎΠ³ΠΎ гипоксиСй Ρ„Π°ΠΊΡ‚ΠΎΡ€Π° HIF-1Ξ±, ΠΌΠΎΠ½ΠΎΡ†ΠΈΡ‚Π°Ρ€Π½ΠΎΠ³ΠΎ хСмотаксичСского Π±Π΅Π»ΠΊΠ° МБР-1 ΠΈ матриксной ΠΌΠ΅Ρ‚Π°Π»Π»ΠΎΠΏΡ€ΠΎΡ‚Π΅ΠΈΠ½Π°Π·Ρ‹ ММР-9 ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΎΠΌ ΠΈΠΌΠΌΡƒΠ½ΠΎΡ„Π΅Ρ€ΠΌΠ΅Π½Ρ‚Π½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π°. Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹ Π°Π½Π°Π»ΠΈΠ·Π° считали достовСрными ΠΏΡ€ΠΈ Ρ€<0,05.Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹. Π£ Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… Π˜Π‘Π‘ ΠΎΠ±Π΅ΠΈΡ… Π³Ρ€ΡƒΠΏΠΏ выявлСно ΠΏΠΎΠ²Ρ‹ΡˆΠ΅Π½Π½ΠΎΠ΅ содСрТаниС дСсквамированных ΠΈ ΠΏΡ€ΠΎΠ³Π΅Π½ΠΈΡ‚ΠΎΡ€Π½Ρ‹Ρ… ΡΠ½Π΄ΠΎΡ‚Π΅Π»ΠΈΠ°Π»ΡŒΠ½Ρ‹Ρ… ΠΊΠ»Π΅Ρ‚ΠΎΠΊ Π² ΠΊΡ€ΠΎΠ²ΠΈ. ΠŸΡ€ΠΈ этом количСство ΠΏΡ€ΠΎΠ³Π΅Π½ΠΈΡ‚ΠΎΡ€Π½Ρ‹Ρ… ΡΠ½Π΄ΠΎΡ‚Π΅Π»ΠΈΠ°Π»ΡŒΠ½Ρ‹Ρ… ΠΊΠ»Π΅Ρ‚ΠΎΠΊ Ρƒ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с ИКМП Π½Π΅ достигало уровня Ρƒ Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… Π˜Π‘Π‘ Π±Π΅Π· ΠΊΠ°Ρ€Π΄ΠΈΠΎΠΌΠΈΠΎΠΏΠ°Ρ‚ΠΈΠΈ, Π° число дСсквамированных эндотСлиоцитов соотвСтствовало Ρ‚Π°ΠΊΠΎΠ²ΠΎΠΌΡƒ. Π’ ΠΊΡ€ΠΎΠ²ΠΈ ΠΏΡ€ΠΈ ИКМП ΠΎΠ±Π½Π°Ρ€ΡƒΠΆΠ΅Π½ Π΄Π΅Ρ„ΠΈΡ†ΠΈΡ‚ нСклассичСских ΠΌΠΎΠ½ΠΎΡ†ΠΈΡ‚ΠΎΠ² ΠΈ HIF-1Ξ±, ΠΏΡ€ΠΈ Π˜Π‘Π‘ Π±Π΅Π· ΠΊΠ°Ρ€Π΄ΠΈΠΎΠΌΠΈΠΎΠΏΠ°Ρ‚ΠΈΠΈ – ΠΈΠ·Π±Ρ‹Ρ‚ΠΎΠΊ ΠΏΡ€ΠΎΠΌΠ΅ΠΆΡƒΡ‚ΠΎΡ‡Π½Ρ‹Ρ… ΠΌΠΎΠ½ΠΎΡ†ΠΈΡ‚ΠΎΠ² ΠΈ МБР-1. ΠšΠΎΠ½Ρ†Π΅Π½Ρ‚Ρ€Π°Ρ†ΠΈΡ ММР-9 Π² ΠΊΡ€ΠΎΠ²ΠΈ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с Π˜Π‘Π‘ соотвСтствовала Π½ΠΎΡ€ΠΌΠ΅ Π²Π½Π΅ зависимости ΠΎΡ‚ наличия ИКМП.Π—Π°ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΠ΅. ΠŸΡ€ΠΈ ИКМП, Π² ΠΎΡ‚Π»ΠΈΡ‡ΠΈΠ΅ ΠΎΡ‚ Π˜Π‘Π‘ Π±Π΅Π· ΠΊΠ°Ρ€Π΄ΠΈΠΎΠΌΠΈΠΎΠΏΠ°Ρ‚ΠΈΠΈ, ΠΏΠΎΠ²Ρ€Π΅ΠΆΠ΄Π΅Π½ΠΈΠ΅ сосудов ассоциировано с Π΄Π΅Ρ„ΠΈΡ†ΠΈΡ‚ΠΎΠΌ нСклассичСских ΠΌΠΎΠ½ΠΎΡ†ΠΈΡ‚ΠΎΠ² ΠΈ ΠΏΠΎΠ½ΠΈΠΆΠ΅Π½Π½ΠΎΠΉ Ρ€Π΅ΠΏΠ°Ρ€Π°Ρ†ΠΈΠ΅ΠΉ эндотСлия, обусловлСнной нСдостаточной ΠΌΠΈΠ³Ρ€Π°Ρ†ΠΈΠ΅ΠΉ ΠΏΡ€ΠΎΠ³Π΅Π½ΠΈΡ‚ΠΎΡ€Π½Ρ‹Ρ… ΡΠ½Π΄ΠΎΡ‚Π΅Π»ΠΈΠ°Π»ΡŒΠ½Ρ‹Ρ… ΠΊΠ»Π΅Ρ‚ΠΎΠΊ ΠΈΠ· костного ΠΌΠΎΠ·Π³Π° Π²Π²ΠΈΠ΄Ρƒ Π΄Π΅Ρ„ΠΈΡ†ΠΈΡ‚Π° HIF-1Ξ± Π² ΠΊΡ€ΠΎΠ²ΠΈ

    CHRONIC COR PULMONALE

    No full text
    Chronic cor pulmonale

    PROSPECTS FOR CYTOPROTECTORS USE IN THE ELDERLY PATIENTS THROUGH THE EXAMPLE OF CALCIFIED AORTIC STENOSIS AND ISCHEMIC HEART DISEASE

    No full text
    Issues of pathogenesis of the calcified aortic stenosis and ischemic heart disease in the elderly are considered. The relevance of early detection of angina, syncope, and dyspnea in view of their non-specific and subclinical course for early detection of heart disease is specified. Current scientific views on the myocardial bioenergy and its role in the genesis of chronic heart failure are presented. Particular attention is paid to the place of cytoprotectors, especially trimetazidine, in the management of patients with cardiac N.Yu. Karpova1diseases.</p

    CORRECTION OF ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH CHRONIC COR PULMONALE BY ANGIOTENSIN II RECEPTORS ANTAGONISTS

    No full text
    Aim. To evaluate intensity of endothelial dysfunction, processes of apoptosis, state of central and peripheral hemodynamics and to evaluate how these characteristics are influenced by angiotensin II receptors antagonists (ARA II) – candesartan (Atacand) and losartan (Cosaar) in patients with chronic cor pulmonale (CCP) at different stages of disease.Material and methods. 100 patients with chronic obstructive pulmonary disease (COPD), complicated by CCP were included into the study. Caspase activity as apoptosis induction marker, von Willebrand factor, production of nitric oxide in blood plasma and condensate of breathing out air were assessed. 70 patients received ARA II (50 patients – candesartan 4-8 mg daily, 20 patients – losartan 50-100 mg daily), 30 patients received neither ARA II nor angiotensin converting enzyme inhibitors (ACEI).Results. Significant increase in intensity of endothelial dysfunction and activation of apoptosis processes were registered according to growth of CCP severity. After 6 months of therapy von Willebrand factor decreased by 25,2% and 27,7% in candesartan and losartan groups respectively (p&lt;0.01 for both groups). In the control group only 13.2% of von Willebrand factor reduction was seen.Conclusion. ARA II added to common therapy of COPD complicated by CCP improves functional state of endothelium restricting hyperproduction of nitric oxide and its toxic effects and slowing down apoptotic cell death

    CORRECTION OF ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH CHRONIC COR PULMONALE BY ANGIOTENSIN II RECEPTORS ANTAGONISTS

    Get PDF
    Aim. To evaluate intensity of endothelial dysfunction, processes of apoptosis, state of central and peripheral hemodynamics and to evaluate how these characteristics are influenced by angiotensin II receptors antagonists (ARA II) – candesartan (Atacand) and losartan (Cosaar) in patients with chronic cor pulmonale (CCP) at different stages of disease.Material and methods. 100 patients with chronic obstructive pulmonary disease (COPD), complicated by CCP were included into the study. Caspase activity as apoptosis induction marker, von Willebrand factor, production of nitric oxide in blood plasma and condensate of breathing out air were assessed. 70 patients received ARA II (50 patients – candesartan 4-8 mg daily, 20 patients – losartan 50-100 mg daily), 30 patients received neither ARA II nor angiotensin converting enzyme inhibitors (ACEI).Results. Significant increase in intensity of endothelial dysfunction and activation of apoptosis processes were registered according to growth of CCP severity. After 6 months of therapy von Willebrand factor decreased by 25,2% and 27,7% in candesartan and losartan groups respectively (p&lt;0.01 for both groups). In the control group only 13.2% of von Willebrand factor reduction was seen.Conclusion. ARA II added to common therapy of COPD complicated by CCP improves functional state of endothelium restricting hyperproduction of nitric oxide and its toxic effects and slowing down apoptotic cell death.</p

    ΠΠ°Ρ€ΡƒΡˆΠ΅Π½ΠΈΡ Ρ€ΠΈΡ‚ΠΌΠ° сСрдца Ρƒ Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… хроничСскими обструктивными болСзнями Π»Π΅Π³ΠΊΠΈΡ…

    Get PDF
    To evaluate frequency, natural history and peculiarities of cardiac arrhythmia in patients with chronic obstructive pulmonary diseases (COPD) under occurring and progressing of chronic cor pulmonale (CCP) 226 patients were examined using daily ECC Holter monitoring, Doppler echocardiography, lung function tests, the blood gas analysis. The data obtained demonstrate a prevalence of supraventricular arrhythmia in COPD patients and suppose that the right heart hypertrophy and/or dilation and the right ventricular diastolic dysfunction greatly contribute to the natural history of supraventricular arrhythmia when CCP developing. Ventricular extrasystole seems to be caused by the left ventricular myocardial metabolic disorders due to the chronic hypoxia.Π‘ Ρ†Π΅Π»ΡŒΡŽ выявлСния частоты, Π³Π΅Π½Π΅Π·Π° ΠΈ особСнностСй Π½Π°Ρ€ΡƒΡˆΠ΅Π½ΠΈΠΉ Ρ€ΠΈΡ‚ΠΌΠ° сСрдца Ρƒ Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… хроничСскими обструктивными болСзнями Π»Π΅Π³ΠΊΠΈΡ… (Π₯ΠžΠ‘Π›) ΠΏΠΎ ΠΌΠ΅Ρ€Π΅ формирования ΠΈ прогрСссирования хроничСского Π»Π΅Π³ΠΎΡ‡Π½ΠΎΠ³ΠΎ сСрдца (Π₯Π›Π‘) обслСдовано 226 ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с Π₯ΠžΠ‘Π›. ВсСм Π±ΠΎΠ»ΡŒΠ½Ρ‹ΠΌ ΠΏΡ€ΠΎΠ²Π΅Π΄Π΅Π½ΠΎ суточноС ΠΌΠΎΠ½ΠΈΡ‚ΠΎΡ€ΠΈΡ€ΠΎΠ²Π°Π½ΠΈΠ΅ ЭК Π“ ΠΏΠΎ Π₯ΠΎΠ»Ρ‚Π΅Ρ€Ρƒ, эходопплСрокардиография, функция внСшнСго дыхания, исслСдовался Π³Π°Π·ΠΎΠ²Ρ‹ΠΉ состав ΠΊΡ€ΠΎΠ²ΠΈ. Наши Π΄Π°Π½Π½Ρ‹Π΅ ΡΠ²ΠΈΠ΄Π΅Ρ‚Π΅Π»ΡŒΡΡ‚Π²ΡƒΡŽΡ‚ ΠΎ ΠΏΡ€Π΅ΠΎΠ±Π»Π°Π΄Π°Π½ΠΈΠΈ Π½Π°Π΄ΠΆΠ΅Π»ΡƒΠ΄ΠΎΡ‡ΠΊΠΎΠ²Ρ‹Ρ… Π°Ρ€ΠΈΡ‚ΠΌΠΈΠΉ Ρƒ Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… Π₯ΠžΠ‘Π› ΠΈ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡŽΡ‚ ΠΏΡ€Π΅Π΄ΠΏΠΎΠ»ΠΎΠΆΠΈΡ‚ΡŒ, Ρ‡Ρ‚ΠΎ ΠΏΡ€ΠΈ Ρ„ΠΎΡ€ΠΌΠΈΡ€ΠΎΠ²Π°Π½ΠΈΠΈ Π₯Π›Π‘ Π² Π³Π΅Π½Π΅Π·Π΅ суправСнтрикулярных Π°Ρ€ΠΈΡ‚ΠΌΠΈΠΉ Π½Π° ΠΏΠ΅Ρ€Π²Ρ‹ΠΉ ΠΏΠ»Π°Π½ Π²Ρ‹ΡΡ‚ΡƒΠΏΠ°ΡŽΡ‚ гипСртрофия ΠΈ/ΠΈΠ»ΠΈ дилатация ΠΏΡ€Π°Π²Ρ‹Ρ… ΠΎΡ‚Π΄Π΅Π»ΠΎΠ² сСрдца ΠΈ Π½Π°Ρ€ΡƒΡˆΠ΅Π½ΠΈΠ΅ диастоличСской Ρ„ΡƒΠ½ΠΊΡ†ΠΈΠΈ ΠΏΡ€Π°Π²ΠΎΠ³ΠΎ ΠΆΠ΅Π»ΡƒΠ΄ΠΎΡ‡ΠΊΠ°, Π° ΠΏΡ€ΠΈ Π– Π­Π‘ вСдущая Ρ€ΠΎΠ»ΡŒ ΠΏΡ€ΠΈΠ½Π°Π΄Π»Π΅ΠΆΠΈΡ‚ мСтаболичСским Π½Π°Ρ€ΡƒΡˆΠ΅Π½ΠΈΡΠΌ ΠΌΠΈΠΎΠΊΠ°Ρ€Π΄Π° Π»Π΅Π²ΠΎΠ³ΠΎ ΠΆΠ΅Π»ΡƒΠ΄ΠΎΡ‡ΠΊΠ° вслСдствиС хроничСской гипоксии
    corecore